DDInter1123 DDInter1934
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chies
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456]
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Mannitol {u} (Compound) palliates {v} (Disease) glaucoma
glaucoma {u} (Disease) is treated by {v} (Compound) Timolol
Timolol {u} may lead to a major life threatening interaction when taken with {v} Vilanterol
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vilanterol
Mannitol {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis
Increased Diuresis {u} (Pharmacologic Class) includes {v} (Compound) Bendroflumethiazide
Bendroflumethiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Mannitol {u} (Compound) palliates {v} (Disease) glaucoma
glaucoma {u} (Disease) is treated by {v} (Compound) Betaxolol
Betaxolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Mannitol {u} (Compound) causes {v} (Side Effect) Discomfort
Discomfort {u} (Side Effect) is caused by {v} (Compound) Bisoprolol
Bisoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Mannitol {u} (Compound) causes {v} (Side Effect) Discomfort
Discomfort {u} (Side Effect) is caused by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vilanterol
Mannitol {u} (Compound) palliates {v} (Disease) glaucoma
glaucoma {u} (Disease) is palliated by {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Mannitol {u} (Compound) causes {v} (Side Effect) Hypovolaemia
Hypovolaemia {u} (Side Effect) is caused by {v} (Compound) Carvedilol
Carvedilol {u} may lead to a major life threatening interaction when taken with {v} Vilanterol
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Carvedilol
Carvedilol {u} may lead to a major life threatening interaction when taken with {v} Vilanterol
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Mannitol (Compound) palliates glaucoma (Disease) and glaucoma (Disease) is treated by Timolol (Compound) and Timolol may lead to a major life threatening interaction when taken with Vilanterol
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Mannitol (Compound) is included by Increased Diuresis (Pharmacologic Class) and Increased Diuresis (Pharmacologic Class) includes Bendroflumethiazide (Compound) and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Mannitol (Compound) palliates glaucoma (Disease) and glaucoma (Disease) is treated by Betaxolol (Compound) and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Mannitol (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Mannitol (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Mannitol (Compound) palliates glaucoma (Disease) and glaucoma (Disease) is palliated by Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Mannitol (Compound) causes Hypovolaemia (Side Effect) and Hypovolaemia (Side Effect) is caused by Carvedilol (Compound) and Carvedilol may lead to a major life threatening interaction when taken with Vilanterol
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carvedilol (Compound) and Carvedilol may lead to a major life threatening interaction when taken with Vilanterol